NYSE American - Delayed Quote USD
CEL-SCI Corporation (CVM)
At close: October 31 at 4:00 PM EDT
Pre-Market: 9:12 AM EDT
Breakdown
TTM
9/30/2023
9/30/2022
9/30/2021
9/30/2020
Operating Expense
27,699.5920
31,476.0740
36,062.7930
36,194.1290
28,985.0550
Operating Income
-27,699.5920
-31,476.0740
-36,062.7930
-36,194.1290
-28,985.0550
Net Non Operating Interest Income Expense
-752.9960
-675.4160
-1,081.0340
-1,149.2880
-1,041.7250
Other Income Expense
10.9110
-42.8130
443.1460
982.3080
-228.4640
Pretax Income
-28,441.6770
-32,194.3030
-36,700.6810
-36,361.1090
-30,255.2440
Net Income Common Stockholders
-29,101.1330
-32,365.8550
-37,629.8030
-36,711.9700
-30,276.9780
Average Dilution Earnings
--
--
--
-1,085.5400
--
Diluted NI Available to Com Stockholders
-29,101.1330
-32,365.8550
-37,629.8030
-37,797.5100
-30,276.9780
Basic EPS
-0.58
-0.73
-0.87
-0.90
-0.82
Diluted EPS
-0.58
-0.73
-0.87
-0.90
-0.82
Basic Average Shares
50,268.4090
44,479.8650
43,148.8880
40,662.1370
36,759.1150
Diluted Average Shares
50,268.4090
44,479.8650
43,148.8880
40,694.2480
36,759.1150
Total Operating Income as Reported
-27,699.5920
-31,476.0740
-36,062.7930
-36,194.1290
-28,985.0550
Total Expenses
27,699.5920
31,476.0740
36,062.7930
36,194.1290
28,985.0550
Net Income from Continuing & Discontinued Operation
-28,441.6770
-32,194.3030
-36,700.6810
-36,361.1090
-30,255.2440
Normalized Income
-28,441.6770
-32,194.3030
-37,067.4720
-37,351.6300
-29,100.4130
Interest Expense
752.9960
675.4160
1,081.0340
1,149.2880
1,041.7250
Net Interest Income
-752.9960
-675.4160
-1,081.0340
-1,149.2880
-1,041.7250
EBIT
-27,688.6810
-31,518.8870
-35,619.6470
-35,211.8210
-29,213.5190
EBITDA
-23,712.4250
-27,560.5530
-31,790.7300
-32,980.7130
-27,053.7900
Reconciled Depreciation
3,976.2560
3,958.3340
3,828.9170
2,231.1080
2,159.7290
Net Income from Continuing Operation Net Minority Interest
-28,441.6770
-32,194.3030
-36,700.6810
-36,361.1090
-30,255.2440
Total Unusual Items Excluding Goodwill
--
--
366.7910
990.5210
-1,154.8310
Total Unusual Items
--
--
366.7910
990.5210
-1,154.8310
Normalized EBITDA
-23,712.4250
-27,560.5530
-32,157.5210
-33,971.2340
-25,898.9590
9/30/2020 - 12/8/1983
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
NWBO Northwest Biotherapeutics, Inc.
0.2700
-0.74%
CTXR Citius Pharmaceuticals, Inc.
0.3727
-7.91%
NRXP NRx Pharmaceuticals, Inc.
1.3700
-4.20%
IMMX Immix Biopharma, Inc.
1.6000
-3.03%
RNAZ TransCode Therapeutics, Inc.
0.4650
-7.74%
ABOS Acumen Pharmaceuticals, Inc.
2.8800
-4.95%
ADIL Adial Pharmaceuticals, Inc.
1.0000
+0.40%
NNVC NanoViricides, Inc.
1.4300
+5.15%
AUPH Aurinia Pharmaceuticals Inc.
7.21
-2.04%
MTNB Matinas BioPharma Holdings, Inc.
0.6200
-67.88%